Effects of new class III antiarrhythmic drug niferidil on electrical activity in murine ventricular myocardium and their ionic mechanisms

被引:0
作者
Denis V. Abramochkin
Vladislav S. Kuzmin
Leonid V. Rosenshtraukh
机构
[1] Lomonosov Moscow State University,Department of Human and Animal Physiology
[2] Pirogov Russian National Research Medical University,Department of Physiology
[3] Institute of Experimental Cardiology,undefined
来源
Naunyn-Schmiedeberg's Archives of Pharmacology | 2015年 / 388卷
关键词
Antiarrhythmic drug; Atrial fibrillation; Action potential; Ionic currents; Atrial-selective;
D O I
暂无
中图分类号
学科分类号
摘要
A new class III antiarrhythmic drug niferidil has been recently introduced as a highly effective therapy cure for cases of persistent atrial fibrillation, but ionic mechanisms of its action are still unknown. Effects of niferidil on action potential (AP) waveform and major ionic currents were studied in mouse ventricular myocardium. APs were recorded with glass microelectrodes in multicellular preparations of right ventricular wall. Whole-cell patch-clamp technique was used to measure K+, Ca2+, and Na+ currents in isolated mouse ventricular myocytes. While 10−7 M niferidil failed to alter the AP configuration, 10−6 M tended to prolong APs (by 12.05 ± 1.8 % at 50 % of repolarization) and 10−5 M induced significant slowing of repolarization (32.1 ± 4.9 % at 50 % of repolarization). Among the potassium currents responsible for AP repolarization phase, IK1 was found to be almost insensitive to niferidil. Ito demonstrated low sensitivity to niferidil with IC50 = 2.03 × 10−4 M. IKur, which was previously hypothesized to be the main target of the drug, was more sensitive with IC50 = 6 × 10−5 M. However, sustained delayed rectifier potassium current Iss was inhibited with even lower IC50 = 2.8 × 10−5 M. Therefore, suppression of Iss and, second, IKur by niferidil seems to underlie the AP prolongation in mouse ventricular tissue. Niferidil also produced a modest decrease in ICaL peak amplitude (IC50≈10−4 M), but failed to alter INa significantly. Niferidil prolongs APs in mouse ventricular myocardium mainly by inhibiting Iss and IKur K+ currents, but not exclusively IKur, as was proposed earlier. Further investigations are required to reveal the mechanisms of niferidil action in human myocardium, where IKr is strongly expressed instead of Iss.
引用
收藏
页码:1105 / 1112
页数:7
相关论文
共 27 条
  • [1] Effects of new class III antiarrhythmic drug niferidil on electrical activity in murine ventricular myocardium and their ionic mechanisms
    Abramochkin, Denis V.
    Kuzmin, Vladislav S.
    Rosenshtraukh, Leonid V.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2015, 388 (10) : 1105 - 1112
  • [2] Influence of New III Class Antiarrhythmic Drug Niferidil (RG-2) on Bioelectrical Activity of Rat Pulmonary Veins Myocardium
    Egorov, Yu. V.
    Stolbova, V. I.
    Kuzmin, V. S.
    Rosenshtraukh, L. V.
    KARDIOLOGIYA, 2012, 52 (02) : 47 - 51
  • [3] A New Class III Antiarrhythmic Drug Niferidil Prolongs Action Potentials in Guinea Pig Atrial Myocardium via Inhibition of Rapid Delayed Rectifier
    Denis V. Abramochkin
    Vladislav S. Kuzmin
    Leonid V. Rosenshtraukh
    Cardiovascular Drugs and Therapy, 2017, 31 : 525 - 533
  • [4] A New Class III Antiarrhythmic Drug Niferidil Prolongs Action Potentials in Guinea Pig Atrial Myocardium via Inhibition of Rapid Delayed Rectifier
    Abramochkin, Denis V.
    Kuzmin, Vladislav S.
    Rosenshtraukh, Leonid V.
    CARDIOVASCULAR DRUGS AND THERAPY, 2017, 31 (5-6) : 525 - 533
  • [5] Effects of a new antiarrhythmic drug SS-68 on electrical activity in working atrial and ventricular myocardium of mouse and their ionic mechanisms
    Bogus, Saida K.
    Abramochkin, Denis V.
    Galenko-Yaroshevsky, Pavel A.
    Suzdalev, Konstantin F.
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2015, 128 (04) : 202 - 207
  • [6] The Dependence of the Electrophysiological Effects of Class III Antiarrhythmic Drug Refralon on the Frequency of Myocardium Activation
    Abramochkin, D. V.
    Pustovit, O. B.
    Mironov, N. Yu.
    Filatova, T. S.
    Kuzmin, V. S.
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2023, 174 (05) : 610 - 615
  • [7] The Dependence of the Electrophysiological Effects of Class III Antiarrhythmic Drug Refralon on the Frequency of Myocardium Activation
    D. V. Abramochkin
    O. B. Pustovit
    N. Yu. Mironov
    T. S. Filatova
    V. S. Kuzmin
    Bulletin of Experimental Biology and Medicine, 2023, 174 : 610 - 615
  • [8] Ionic Mechanisms of Action of Class III Antiarrhythmic Drugs
    Kuzmin, V. S.
    Rosenshtraukh, L. V.
    KARDIOLOGIYA, 2010, 50 (07) : 49 - 61
  • [9] Electropharmacology of nifekalant, a new class III antiarrhythmic drug
    Nakaya, H
    Uemura, H
    CARDIOVASCULAR DRUG REVIEWS, 1998, 16 (02): : 133 - 144
  • [10] Refralon (niferidil) is a new class III antiarrhythmic agent for pharmacological cardioversion for persistent atrial fibrillation and atrial flutter
    Maykov, E. B.
    Yuricheva, Yu. A.
    Mironov, N. Yu.
    Sokolov, S. F.
    Golitsyn, S. P.
    Rozenshtraukh, L. V.
    Chazov, E. I.
    TERAPEVTICHESKII ARKHIV, 2015, 87 (01) : 38 - 48